Immune-Related Response Criteria
Immune-Related Response Criteria
复制标题
DOI：
10.32388/idc6mf
复制
发表时间：
2020-02
期刊：
影响因子：
--
通讯作者：
P. Therasse
中科院分区：
文献类型：
--
作者：
P. Therasse
抗癌剂可以产生的肿瘤缩小量是在临床试验中评估其有效性的过程中测量的。世界卫生组织的标准是由国际抗癌联合会和世界卫生组织在20世纪70年代创建的，是第一个被广泛认可的肿瘤反应评估编码化的基本标准。这些标准于1981年首次公布。2000年首次发表的RECIST标准修订了世界卫生组织的标准，主要是为了澄清研究小组之间仍然存在的差异。
The amount of tumour shrinkage that anti-cancer agents can produce is measured as part of the process of evaluating their efficacy in clinical trials. The WHO Criteria, created by the International Union against Cancer and the World Health Organization in the 1970s, were the first widely agreed-upon basic criteria for the codification of tumour response evaluation. These criteria were first published in 1981. The RECIST criteria, first published in 2000, revised the WHO criteria primarily to clarify differences that remained between research groups.